Endo International plc ENDP announced positive data from a phase IIb study of Xiaflex (clostridium histolyticum collagenase) for the treatment of patients suffering from fibrosclerotic pannicopathy, also known as cellulitis.
The data showed that patients treated with Xiaflex showed a statistically significant improvement in the primary endpoint of the composite investigator and patient assessments of the appearance of cellulite, compared to those treated with placebo. The study also met all secondary endpoints. In terms of safety, Xiaflex was found to be well tolerated.
Based on the study’s encouraging results, Endo plans to work with the FDA to advance Xiaflex as a late-stage cellulite treatment.
According to the company’s press release, there is currently no FDA-approved pharmacological treatment despite multiple therapeutic approaches to attempt to treat cellulite.
We note that Xiaflex is currently approved in the US and EU for the treatment of Dupuytren’s contracture in adult patients with palpable cord and Peyronie’s disease in adult men with palpable plaque and penile curvature deformity of at least 30 degrees at the start of treatment. Xiaflex enjoys Orphan Drug status for both indications in the US
Endo currently carries a Zacks Rank #3 (Hold).
ENDO INTL PLC price
ENDO INTL PLC Price | ENDO INTL PLC offer
Stocks to consider
Some top-ranked healthcare stocks include Incyte Corporation INCY, Anika Therapeutics ANIK, and Exelixis, Inc. EXEL. All three stocks carry a Zacks Rank #2 (Buy). You can see the full list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates rose from 20 cents to 68 cents for 2016 and from $1.42 to $1.70 for 2017 over the past 60 days. The company posted a positive average of 431.43% over the past four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 in the last 60 days. The company posted a positive surprise in all the last four quarters with an average of 33.14%. Its share price is up 18.2% year to date.
Exelixis’ loss estimates were cut from 65 cents to 51 cents for 2016 and from 7 cents to 4 cents earnings for 2017 over the past 60 days. The company has posted a positive surprise three times in the last four quarters with an average of 38.52%. Its stock price has soared over 150% year-to-date.
Zacks Confidential
In addition to this Analyst Blog, would you like to see the best Zacks Picks that are not available to the public? Our executive vice president, Steve Reitmeister, knows when key trades are going to be triggered and which of our experts has the hottest hand. Click to view them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download the 7 best stocks for the next 30 days. Click to get this free report
INCYTE CORP (INCY): Free Stock Analysis Report
EXELIXIS INC (EXEL): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ENDO INTL PLC (ENDP): Free Stock Analysis Report
